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*oninvasive Risk
ssessment Early After
Myocardial Infarction
re We Looking
t the Right Indicators?
xner et al. (1) looked at the role of combined assessment of
utonomic tone plus cardiac electrical substrate as markers of predict-
ng long-term mortality in evaluating 322 patients who survived
yocardial infarction (MI) but with left ventricular (LV) dysfunction.
e have 3 concerns about this study. First, the authors fail to report
he incidence of nonsustained ventricular tachycardia in study pa-
ients. Nonsustained ventricular tachycardia has already been proved
s an electric substrate and an indicator of high mortality in patients
ith LV dysfunction (2). Second, there is no information on the use
f antiarrhythmic drugs in study patients, which might very well affect
he outcome. Third, most patients in the study (81%) underwent
evascularization by percutaneous coronary intervention, and the
uthors reported a significant increase in left ventricular ejection
raction over the initial 2 months after MI. Distal embolization is a
nown complication of percutaneous coronary intervention. Distal
mbolization is a phenomenon in which macro emboli from the
riginal lesion migrate distally, causing micro-infarcts leading to
nadequate flow at the tissue level despite reopened epicardial coronary
rtery. It is related to reduced myocardial reperfusion and a poor
rognosis (3), but the authors did not report any data about it. These
icro-infarcts could be playing a role in some of the unexplained
ncrease in mortality in post-MI patients, even though the left
entricular ejection fraction is improved significantly. There is a need
o assess the effect of these confounding variables, to truly determine
hemost accurate and clinically feasible noninvasive markers to predict
ong-term prognosis after MI. A study that combines clinical, elec-
rophysiological, and imaging (echocardiography and angiography)
ata to assess the long-term prognosis after MI is warranted.
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e thank Drs. Goyal and Punnam for their interest in our study (1).
he prevalence and prognostic significance of nonsustained ventric-
lar tachycardia (NSVT) was evaluated in the REFINE (Risk
stimation Following Infarction, Noninvasive Evaluation) study, but
hese data were not included, owing to space limitations. At 10 to 14
eeks after the index myocardial infarction (MI), 95 of the 322
atients (30%) had 1 or more NSVT episodes lasting at least 5 beats.
he prevalence of NSVT did not differ among patients who suffered
he primary outcome of cardiac death or nonfatal cardiac arrest (p 
.3) versus patients who did not. Also, NSVT was not associated with
significantly higher risk of the primary outcome (hazard ratio [HR]
.8, 95% confidence interval [CI] 0.8 to 3.8; p  0.1). Importantly,
he association between Holter-assessed impaired heart rate turbu-
ence plus abnormal repolarization alternans with an increased risk of
he primary outcome (HR 5.0, 95% CI 2.3 to 10.7; p  0.0001) was
ot altered when NSVT was adjusted for (HR 4.9, 95% CI 2.3 to
0.6; p  0.0001).
Antiarrhythmic drug use was uncommon in the REFINE study; 6
atients (2%) received amiodarone and 3 (1%) received sotalol.
ntiarrhythmic drug use was similar in patients who did versus did
ot suffer the primary outcome (p 0.2) and was not associated with
n increased risk of the primary outcome (HR 1.6, 95% CI 0.2 to
2.5; p 0.6). As with NSVT, the association of impaired heart rate
urbulence plus abnormal repolarization alternans with an increased
isk of the primary outcome was not altered when antiarrhythmic drug
sage was adjusted for (HR 5.4, 95% CI 2.3 to 12.6; p  0.0001).
We did not evaluate distal embolization in the REFINE study,
ecause we sought to assess markers of long-term risk. Multiple
tudies have shown that distal embolization impacts short-term 30- to
0-day risk of adverse clinical outcomes and not long-term 4-year risk
2,3). The strong association between impaired heart rate turbulence
lus abnormal repolarization alternans with an increased risk of the
rimary outcome was not altered when change in ejection fraction
ver the initial 2 months after MI, a surrogate of successful reperfu-
ion, was adjusted for (HR 5.1, 95% CI 2.2 to 11.9; p  0.0001).
In conclusion, the concerns of Drs. Goyal and Punnam do not
etract from our findings. As clearly demonstrated (1), the combina-
ion of impaired heart rate turbulence plus abnormal repolarization
lternans assessed in the nonacute post-MI period reliably predicts the
ong-term risk of serious outcomes. Thus, we believe these markers
re the right indicators.
Derek V. Exner, MD, MPH
n behalf of the REFINE Investigators
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o Conflicts of Interest
eally Matter or Does No One
ead the Fine Print Anyway?
t is with interest that I read the expedited publication on the recently
nacted “black box” warnings on perflutren-containing ultrasound
ontrast agents in the December 18/25, 2007 issue of the Journal (1).
After reading the informative piece, which I believe enhanced
y understanding on the issue at hand, I glanced over the authors’
onflict-of-interest information near the bottom of the page (i.e.,
he fine print). I was surprised to find that 2 of the 3 authors are
aid consultants of Bristol-Myers Squibb Medical Imaging (who
anufactures Definity), and all 3 have some form of financial
nvolvement in the field of perflutren-containing ultrasound con-
rast agents. Although I have no issues with the decision to publish
his timely information, I cannot comprehend why an opinion
iece is solicited from authors who have direct financial relation-
hips with the companies manufacturing the products in question.
Does anyone read the conflict-of-interest fine print? And if not,
hat is its purpose? I believe stricter journal policies need to be
stablished for publication of opinion pieces that specifically focus on
crutinizing authors’ financial relationships with drug and device
anufacturers. How else is the average, unseasoned reader meant to
ppreciate the degree to which, if any, these authors’ comments have
een altered or encouraged by their conflicted interests?
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righam & Women’s Hospital
arvard Medical School
5 Francis Street
oston, Massachusetts 02115
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. Main ML, Goldman JH, Grayburn PA. Thinking outside the “box”—the
ultrasound contrast controversy. J Am Coll Cardiol 2007;50:2434–7.
eply
e appreciate Dr. Vorobiof’s comments regarding our recent
aper (1). Although he found the paper “informative” and believes
t enhanced his understanding, he wishes it had been written by
uthors free of potential financial conflicts of interest.
Potential conflicts of interest are ubiquitous in medicine (and life).
ost clinical research involves collaboration between physicians and
ndustry, many National Institutes of Health-sponsored clinical trials
nclude industry support, and the majority of manuscript reviewers
onsidered “expert” on a particular topic also have potential conflicts.
o deal with this complex issue, the American College of Cardiology
oundation and the American Heart Association (2), the Heart
ditors Action Roundtable (3), and the Journal (4,5) all mandate full
isclosure of any potential financial conflicts of interest at the time of
anuscript submission, a policy with which we were compliant. To
ur knowledge, no one besides Dr. Vorobiof has suggested that
uthors with potential conflicts of interest be excluded from publish-
ng in medical journals. To do so would virtually abolish published
cientific reports, to the great detriment of medical science.
Finally, we want to correct the assertion that our manuscript was
olicited by the Journal. It was not. Additionally, no industry repre-
entative suggested, supported, or reviewed the manuscript. Our
rincipal “conflict of interest” is the safety and well being of patients,
o whom we are morally and professionally obligated to provide the
est care possible. If ultrasound contrast agents were unsafe for clinical
se, we would be the first to demand their removal from the market.
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